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Abstract
Introduction: Adjuvant treatment with tamoxifen substantially improves survival of women with estrogen-receptor
positive (ER+) tumors. Tamoxifen resistance (TAMR) limits clinical benefit. RRR-a-tocopherol ether-linked acetic acid
analogue (a-TEA) is a small bioactive lipid with potent anticancer activity. We evaluated the ability of a-TEA in the
presence of tamoxifen to circumvent TAMR in human breast cancer cell lines.
Methods: Two genotypically matched sets of TAM-sensitive (TAMS) and TAM-resistant (TAMR) human breast
cancer cell lines were assessed for signal-transduction events with Western blotting, apoptosis induction with
Annexin V-FITC/PI assays, and characterization of cholesterol-rich microdomains with fluorescence staining. Critical
involvement of selected mediators was determined by using RNA interference and chemical inhibitors.
Results: Growth-factor receptors (total and phosphorylated forms of HER-1 and HER-2), their downstream
prosurvival mediators pAkt, pmTOR, and pERK1/2, phosphorylated form of estrogen receptor-a (pER-a at Ser-167
and Ser-118, and cholesterol-rich lipid microdomains were highly amplified in TAMR cell lines and enhanced by
treatment with TAM. a-TEA disrupted cholesterol-rich microdomains, acted cooperatively with TAM to reduce
prosurvival mediators, and induced DR5-mediated mitochondria-dependent apoptosis via an endoplasmic
reticulum stress-triggered pro-death pJNK/CHOP/DR5 amplification loop. Furthermore, methyl-b-cyclodextrin
(MbCD), a chemical disruptor of cholesterol rich microdomains, acted cooperatively with TAM to reduce prosurvival
mediators and to induce apoptosis.
Conclusions: Data for the first time document that targeting cholesterol-rich lipid microdomains is a potential
strategy to circumvent TAMR, and the combination of a-TEA + TAM can circumvent TAMR by suppression of
prosurvival signaling via disruption of cholesterol-rich lipid microdomains and activation of apoptotic pathways via
induction of endoplasmic reticulum stress.
Introduction
Of the estimated 207,090 new cases of breast cancer
diagnosed among women in the United States in 2010,
approximately 70% were ER+ [1]. Unfortunately, 40% to
50% of ER+ breast cancer patients either will not
respond to endocrine therapy (that is, exhibit de novo
resistance) or will have cancer recurrence because of
acquired endocrine therapy resistance [2]. Clearly, more
basic science information and different treatment regi-
mens are needed to circumvent endocrine therapy
resistance.
TAM is a selective estrogen-receptor modulator with
estrogenic actions in endometrial tissue, adipose tissue,
and bone, and anti-estrogenic actions in breast tissue
[3]. TAM, which binds to ER-a and antagonizes ER-a
actions in breast tissue, has been the mainstay of endo-
crine therapy in both early and advanced ER+ breast
cancer patients for almost three decades. However,
TAM resistance remains the major barrier for its suc-
cessful application in the clinic. De novo and acquired
resistance may occur through altered cell-signaling med-
iators, leading to estrogen-independent activation of ER-
mediated gene expression and hormone independence
[4]. Of the many events producing TAMR, aberrant
overexpression of prosurvival signaling is implicated as
an important contributor to both acquired and de novo
TAMR [5,6]. TAMR cells have been shown to
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HER-1 and HER-2, and to crosstalk with membrane-
associated ER (mER), leading to nuclear estrogen-recep-
tor (nER) dependent and independent cell proliferation
in which TAM acts as an agonist [6-8].
Cholesterol-enriched lipid-raft microdomains are char-
acterized as lateral assemblies of glycosphingolipids and
cholesterol that form liquid-ordered membrane phases
with detergent-resistant structures. Cholesterol-enriched
domains are highly expressed in tumor cells [9,10] and
provide the necessary platforms for growth factors,
RTKs, and their downstream mediators, such as Akt
a n dE R K( R T K s / A k ta n dR T K s / E R Kc o m p l e x e s ) ,t o
interact and crosstalk, leading to cell proliferation and
survival [10,11]. Therefore, cholesterol-enriched lipid-
raft domains are described as “survival pools” for pro-
moting prosurvival and pro-proliferation pathways, both
of which are targets for cancer prevention and therapy.
a-TEA, a unique small pleiotropic-acting lipid, has
been shown to possess anticancer properties that are
selective for cancer cells and not normal cells and that
are nontoxic both in vitro and in vivo [12-24]. Mechan-
istic studies show that a-TEA has two major effects that
are necessary and sufficient for inducing apoptosis of
cancer cells: (a) activation of proapoptotic pathways
including Fas receptor (FasR)/Fas ligand (Fas L), endo-
plasmic reticulum stress-mediated JNK/CHOP/DR5 and
p73/Noxa, leading to caspase-8 and mitochondria-
dependent apoptosis, and (b) suppression of prosurvival/
antiapoptotic factors such as HER-1, HER-2, Akt, ERK,
cellular FLICE-inhibitory protein (c-FLIP), and B-cell
lymphoma 2 (Bcl-2), and survivin [13,18-24]. Addition-
ally, a-TEA has been shown to stimulate antitumor
immune responses [25].
Data presented here show that a-TEA circumvents
TAMR in the presence of TAM via activation of endo-
plasmic reticulum stress-mediated DR5-dependent proa-
poptotic signaling and disruption of cholesterol-rich




a-TEA (F.W. = 488.8) was prepared in our laboratory as
previously described [16]. Tamoxifen was purchased
from Calbiochem (La Jolla, CA). Filipin, methyl-b-cyclo-
dextrin (MbCD) and cholesterol were purchased from
Sigma (St. Louis, MO). Dialkylindocarbocyanine (DilC-
16) was purchased from Molecular Probes (Eugene, OR).
Cell culture and treatments
TAM-sensitive MCF-7/parental (MCF-7/TAMS) and
acquired tamoxifen-resistant MCF-7 (MCF-7/TAMR)
cells were a gift from Dr. Linda A. deGraffenried
(University of Texas at Austin). MCF-7/TAMS cells were
cultured as previously described [23]. MCF-7/TAMR
cells were grown in phenol-red-free improved modified
Eagle’s medium (IMEM) with 10% charcoal stripped
(steroid-depleted) serum supplemented with TAM (10
-7
M). [Note: TAM is required to maintain the TAMR phe-
notype of MCF-7/TAMR cells in culture]. Three days
before treatment, cells were grown in phenol-red-free
IMEM with 10% charcoal-stripped serum supplemented
with 17-b-estradiol (10
-9 M) for MCF-7/TAMS and
TAM (10
-7 M) for MCF-7/TAMR. Clone 18 MCF-7 cells
overexpressing HER-2 (MCF-7/HER-2) that exhibit a
TAMR phenotype [8] and their vector control (MCF-7/
Neo) cells (gifts from Dr. Mien-Chie Hung, MD Ander-
son, Houston, TX) were cultured under the same condi-
tion as MCF-7/TAMS. During treatments, serum was
reduced to 2% without TAM. Cells were treated with var-
ious concentrations of TAM, a-TEA, or vehicle (VEH)
control. Neither TAM nor a-TEA is water soluble, so
they are solubilized in ethanol before addition to media
and an ethanol control (called vehicle), consisting of the
highest concentration of ethanol used for solubilization
in a given experiment, was included as a control.
Western blot analyses
Western blot analyses were conducted as described pre-
viously [22]. Antibodies to the following proteins were
used: poly (ADP-ribose) polymerase (PARP), c-FLIP,
CHOP, glucose-regulated protein (GRP-78), pERK, total
ERK (tERK), and pJNK (Santa Cruz Biotechnology, Santa
C r u z ,C A ) ,B c l - 2 ,c a s p a s e - 8 ,c a s p a s e - 9 ,D R 5 ,p h o s p h o -
HER-1 (pHER-1), total HER-1 (tHER-1), phospho-HER-2
(pHER-2), total HER-2 (tHER-2), pER-a (Ser-118), pER-
a (Ser-167), total ER-a (tER-a), pAkt (Ser-473), total Akt
(tAkt), and glyceraldehyde-3-phosphate dehydrogenase
(GAPDH) (Cell Signaling Technology, Beverly, MA).
RNA interference
A scrambled RNA duplex that does not target any
known gene was used as the nonspecific negative con-
trol for RNA interference (referred to as control siRNA).
Transfection of MCF-7/TAMR cells with siRNAs to
D R 5 ,C H O P ,J N K ,A k t - 1 ,c - F L I P ,o rc o n t r o l( A m b i o n ,
Austin, TX) was performed as previously described [22].
Quantification of apoptosis
Apoptosis was quantified with the Annexin V-FITC/PI
assay (Invitrogen, Carlsbad, CA) by following manufac-
turer’s instructions. Data were analyzed by using Cell-
Quest software (BD Biosciences, San Jose, CA).
Staining with fluorescent-labeled DilC-16 and Filipin
Fluorescein-labeled lipid analogue DilC-16, a lipid
microdomain marker [26], and fluorescein-labeled
Tiwary et al. Breast Cancer Research 2011, 13:R120
http://breast-cancer-research.com/content/13/6/R120
Page 2 of 12Filipin, a cholesterol marker [27], were used to deter-
m i n et h ep r e s e n c eo fc h o l e s t erol-enriched lipid micro-
domains. For DilC-16 staining, cells were trypsinized
and washed with phosphate-buffered saline (PBS) and
stained with DilC-16 (5 μM)f o r1 5m i n u t e sa tr o o m
temperature. For filipin staining, cells were trypsinized,
washed with PBS, fixed with 3% paraformaldehyde for
30 minutes at room temperature, rinsed with PBS, and
incubated with 1.5 mg/ml glycine in PBS to quench the
paraformaldehyde. Cells were then stained with fluores-
cein-labeled filipin (50 μg/ml) for 1 hour at room tem-
perature and washed with PBS. Cells were viewed by
using a fluorescence microscope with TRITC filter set-
ting for DiLC-16 staining and UV filter setting for filipin
staining, respectively.
Statistical analysis
One-way analysis of variance (ANOVA) followed by
Tukey test was used for comparison of more than two
treatments to determine statistical differences. Differ-
ences were considered statistically significant at P < 0.05.
Results
TAMR cells in comparison with TAMS cells constitu-
tively express higher levels of prosurvival mediators and
cholesterol-enriched lipid microdomains
Total and phosphorylated protein profiles of prosurvi-
val mediators in both de novo and acquired TAMR cell
lines (MCF-7/HER-2 and MCF-7/TAMR, respectively),
cultured with and without TAM, in comparison with
their parental TAMS cells, were determined by Western
blot analyses. Growth-factor receptors HER-1 and HER-
2 (phosphorylated form as well as total protein) and
their downstream mediators pAkt and pERK1/2, as well
as pER-a (Ser-167 and Ser-118) are expressed at mark-
edly higher levels in TAMR cells in comparison with
their parental TAMS cells (Figure 1a). pHER-1 and
pHER-2 were below levels of detection in the TAMS
cell lines either with or without TAM treatment (Figure
1a). As expected, TAM treatment reduced levels of acti-
vated Akt (pAkt) and activated ER-a (pER-a Ser-167
and Ser-118) in both TAMS cell lines, but had the
opposite effect on the TAMR cells, measurably enhan-
cing activated pAkt and pER-a (Ser-167 and Ser-118) in
TAMR cells (Figure 1a). These data document that pro-
survival signaling is constitu t i v e l yh i g h l ye x p r e s s e di n
TAMR cells in comparison with TAMS cells, and that
TAM treatment differentially affects prosurvival signal-
ing between TAMS and TAMR cells; TAM downregu-
lates prosurvival mediators in TAMS cells and increases
them in TAMR cells. Furthermore, both TAMR cell
lines express higher levels of the fluorescent lipid analo-
gue DilC-16, a marker of lipid microdomains, and fluor-
escein-labeled filipin, a cholesterol marker, as viewed by
using a fluorescence microscope in comparison with
TAMS cells (Figure 1b and 1c), suggesting that TAMR
cells constitutively express higher levels of cholesterol-
enriched lipid rafts that are supportive of prosurvival
signaling.
Figure 1 TAMR cells in comparison to TAMS cells constitutively
express higher levels of prosurvival mediators and cholesterol-
rich lipid microdomains. (a) TAMR cell lines MCF-7/TAMR and
MCF-7/HER-2, as well as TAMS parental MCF-7/TAMS and MCF-7/
Neo cells, were treated with TAM at 1 μM or VEH (ethanol) in
steroid-depleted media containing 17b-estradiol (10
-9 M) for 2 days.
Molecular profile of prosurvival mediators was determined with
Western blot analyses. (pHER-1/tHER-1 and pHER-2/tHER-2 were not
detected in the MCF-7/TAMS and MCF-7/Neo cells). (b) The
expression of lipid microdomains was determined by staining the
cells with fluorescein-tagged DiLC16 lipid-raft marker and viewed
with a fluorescence microscope. (c) The expression of cholesterol-
rich lipid microdomains was determined by staining cells with
fluorescein-labeled filipin, a cholesterol marker, and viewed by using
a fluorescence microscope. (a-c) Data are representative of a
minimum of three independent experiments. DiIC-16,
dialkylindocarbocyanine; HER, human epidermal growth factor; MCF-
7/HER-2, Clone 18 MCF-7 cells overexpressing HER-2; MCF-7/TAMR,
acquired tamoxifen-resistant MCF-7; MCF-7/TAMS, TAM-sensitive
MCF-7/parental; pHER-1, phosphorylated-HER-1; pHER-2,
phosphorylated-HER-2; TAM, tamoxifen; TAMR, tamoxifen resistant;
TAMS, tamoxifen sensitive; VEH, vehicle control.
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induction of apoptosis and suppression of proliferation/
survival signaling
To determine whether cholesterol-rich lipid microdo-
mains play a critical role in elevated expression of pro-
survival mediators in TAMR cells, TAMR cells were
cultured with the cholesterol-depleting agent MbCD fol-
lowed by analyses of proliferation/survival mediators.
MbCD at 2.5 and 5 μM suppressed levels of total and
pHER-1 and pHER-2, and decreased levels of pAkt and
pER-a (Ser-118 and Ser-167) in MCF-7/TAMR cells
(Figure 2a). MbCD at 1.25 or 2.5 μM in the presence of
0.5 or 1 μM TAM acted cooperatively to induce apopto-
sis significantly in bothM C F - 7 / T A M Ra n dM C F - 7 /
HER-2 cells in comparison with single treatments, as
determined with Annexin V-FITC/PI analyses (Figure
2b) and cleavage of PARP, an indicator of apoptosis
(Figure 2c). Furthermore, although 1 μM TAM treat-
ment produced a trend toward increased levels of prolif-
eration/survival mediators, MbCD alone produced a
trend of decreased expression of proliferation/survival
mediators, and the combination of MbCD + TAM acted
cooperatively to produce the most marked reduction in
proliferation/survival mediators (Figure 2c), indicating
that MbCD restores TAM sensitivity. Taken together,
these data demonstrate that MbCD disruption of choles-
terol-rich lipid microdomains circumvents TAMR when
combined with TAM via suppression of prosurvival sig-
naling and induction of apoptosis, providing additional
support that cholesterol-enriched lipid microdomains
participate in TAM resistance via enhancing prolifera-
tion/prosurvival signaling in TAMR cells.
a-TEA cooperates with TAM to induce apoptosis in TAMR
cell lines
a-TEA induces apoptosis in a dose-dependent manner
in both TAMR and TAMS cells (Figure 3a). a-TEA
treatment of MCF-7/TAMR and MCF-7/HER-2 at 10,
20, and 40 μM significantly induced apoptosis in com-
parison with VEH control. As expected, TAM induced
apoptosis only in TAM-sensitive MCF-7/parental cells,
and not in either of the TAM-resistant cell lines (neither
TAMR MCF-7/TAMR nor MCF-7/HER-2 cells (data
not shown). To determine whether TAM can act coop-
eratively with a-TEA to trigger TAM-resistant cells to
undergo apoptosis, we examined the combination effect
of three nonapoptotic doses of tamoxifen (0.5, 1, and
1.5 μM) with three sub-half-maximal effective concen-
tration (EC50) apoptotic doses of a-TEA (10, 20, and 30
μM) on induction of apoptosis. The combination of a-
TEA at 10, 20, and 30 μM plus TAM at 0.5, 1, and 1.5
μM, respectively, significantly increased the levels of
apoptosis (Figure 3b) and cleaved PARP (c-PARP)
(Figure 3c) in MCF-7/TAMR and MCF-7/HER-2 cells in
comparison with VEH control and single treatments.
We determined the proapoptotic effect obtained with
TAM and a-TEA combination by using the CalcuSyn
(Biosoft, Manchester, UK) software package, which is
designed to calculate combination indexes (CIs) by
using the Chou-Talalay method for drug-combination
efficacy based on the median-effects equation [28]. CI
values of 0.59 ± 0.00 and 0.81 ± 0.13 indicated synergis-
tic actions of a-TEA + TAM (20:1 ratio) on induction
of apoptosis in MCF-7/TAMR and MCF-7/HER-2 cell
lines, respectively (Table 1). The cooperative proapopto-
tic actions of the combination of a-TEA plus TAM
were further confirmed by measurement of increased
levels of cleaved caspases-8 and -9 (c-caspase-8 and -9)
(Figure 3c), suggesting that the combination of a-TEA +
TAM induces caspase-8 and -9 mediated apoptosis in
both TAMR cell lines.
Combination of a-TEA + TAM acted cooperatively to
induce endoplasmic reticulum stress-mediated apoptosis
Because a-TEA has been shown to induce endoplasmic
reticulum stress [18], we wanted to explore the possibi-
lity that a-TEA + TAM were inducing endoplasmic reti-
culum stress-mediated apoptosis. Combination of 20 μM
a-TEA + 1 μM TAM induced increased levels of endo-
plasmic reticulum stress-associated proapoptotic factors,
pJNK (2/1), CHOP, and DR5 long and short (L/S) and
endoplasmic reticulum stress marker GRP78 in both
TAMR cell lines (Figure 4a). siRNAs to CHOP, DR5,
and JNK blocked the ability of the combination treat-
ment to induce apoptosis, as determined by the absence
of cleaved PARP and blockage of combination treat-
ment-induced increases in pJNK (2/1), CHOP, and DR5
(L/S) in the MCF-7/TAMR cell line (Figure 4b), indicat-
ing that the combination of a-TEA + TAM enhances a-
TEA-induced endoplasmic reticulum stress-mediated
apoptosis, which involves JNK/CHOP/DR5.
Combination of a-TEA + TAM circumvents TAMR via
cooperatively suppressing prosurvival/antiapoptotic
factors
As shown in Figure 1a, TAM induces the expression of
prosurvival mediators HER-1 and HER-2 (total and
phosphorylated forms), as well as pAkt, pERK2/1, and
pER-a (Ser 167 and 118) in TAMR cells. Importantly,
a-TEA alone and, even more markedly, when in combi-
nation with TAM, reduced the expression of these pro-
liferation/survival mediators (Figure 5a), indicating that
a-TEA restores TAM sensitivity in TAMR cells by
downregulating survival factors. Moreover, TAM alone
induced increased levels of antiapoptotic factors c-FLIP
and Bcl-2 (Figure 5b), suggesting that these
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Page 4 of 12Figure 2 Methyl-b-cyclodextrin (MbCD), a known cholesterol-rich membrane domain disruptor, reduces levels of prosurvival mediators
and, in combination with TAM, induces apoptosis and reduces levels of prosurvival mediators. (a) MCF-7/TAMR cells were treated with
MbCD at 2.5 and 5.0 μM for 1 day. Protein levels of prosurvival signaling mediators were determined with Western blot analyses. (b) MCF-7/
TAMR and MCF-7/HER-2 cells were treated with TAM at 0.5 or 1 μM with and without MbCD at 1.25 or 2.5 μM for 1 day. Apoptosis was
determined with Annexin V/PI. (c) Western blot analyses were performed to determine the prosurvival signaling mediators in both TAMR cell
lines treated separately and in combination with 1 μM TAM and 2.5 μM MbCD for 1 day. Data in (a) and (c) are representative of two individual
experiments. Data in (b) are depicted as mean ± SD of three individual experiments. *Significantly different in comparison with TAM or MbCD
treatment alone; P < 0.05. TAM, tamoxifen; TAMR, tamoxifen resistant; MCF-7/HER-2, clone 18 MCF-7 cells overexpressing HER-2; MCF-7/TAMR,
acquired tamoxifen-resistant MCF-7.
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signaling. Again, the combination of a-TEA + TAM
acted cooperatively to suppress these antiapoptotic fac-
tors (Figure 5b).
In an effort to understand how TAM cooperates with
a-TEA to induce endoplasmic reticulum stress and
endoplasmic reticulum stress-mediated JNK/CHOP/
DR5, we knocked down Akt-1 and c-FLIP by using
siRNA to examine the impact on a-TEA-mediated upre-
gulation of JNK1/2, CHOP, DR5, and GRP-78 protein
levels. siRNAs to Akt-1 and c-FLIP enhanced a-TEA-
induced apoptosis, as detected by PARP cleavage (Figure
5c), as well as enhanced the a-TEA ability to increase
protein levels of JNK1/2, CHOP, DR5(L/S), and GRP-78
(Figure 5c). siRNA to Akt-1 reduced pAkt levels and
reduced c-FLIP expression, and the combination of a-
TEA + siRNA to Akt-1 acted cooperatively to suppress
pAkt further and to reduce c-FLIP expression (Figure
5c). siRNA to c-FLIP reduced c-FLIP protein levels, but
not pAkt, and acted cooperatively with a-TEA to reduce
further the c-FLIP expression as well as to reduce pAkt
levels (Figure 5c). These data suggest that c-FLIP is
regulated, at least in part, by Akt-1, and downregulation
of Akt/c-FLIP contributes to the a-TEA ability to upre-
gulate pJNK, CHOP, DR5, and GRP78. Taken together,
data presented in Figure 5 demonstrate that the combi-
nation of a-TEA + TAM acts cooperatively to suppress
markedly both prosurvival and antiapoptotic signaling
mediators.
Reductions in cholesterol-rich lipid-raft domains are
involved in a-TEA + TAM circumvention of TAMR
Cholesterol-rich lipid microdomains support cell prolif-
eration and cell survival. As detected by staining cells
with the cholesterol marker filipin, treatment with a-
TEA in comparison with VEH control produced reduc-
tions in cholesterol-rich microdomains (Figure 6a). Pre-
treatment of MCF-7/TAMR cells with 10 μM
exogenous cholesterol, an established method for enhan-
cing cholesterol-rich microdomains [29] for 2 hours
blocked the ability of both a-TEA alone and the combi-
nation of a-TEA + TAM to induce apoptosis, as
detected by PARP cleavage (Figure 6b); as well as to
decrease protein levels of prosurvival signaling media-
tors (Figure 6b). These data suggest that cholesterol-rich
lipid microdomains are important for a-TEA + TAM
circumvention of TAMR.
Discussion
Acquired and de novo tamoxifen resistance are major
barriers for successful application of tamoxifen in the
clinic. Data reported here document that TAMR cells
constitutively express highlye l e v a t e dg r o w t h - f a c t o rs i g -
naling mediators that can be depleted by reducing cho-
lesterol-rich microdomains and that a-TEA, a small
bioactive lipid, in combination with TAM, restores
TAM sensitivity to TAMR cells via suppression of
TAMR proliferation/survival mediators and induction of
cell death by apoptosis. Novel findings from these stu-
dies are as follows: (a) TAMR cells express higher levels
of cholesterol-rich lipid microdomains than do TAMS
cells; (b) disrupting cholesterol-rich lipid microdomains
with the cholesterol-depleting agent MbCD suppressed
TAMR prosurvival signaling and induced apoptosis
when combined with TAM; (c) treating TAMR cells
with the unique anticancer agent a-TEA alone reduced
cholesterol-rich lipid microdomains, reduced levels of
constitutively expressed pro-proliferation/prosurvival
signaling mediators, and led to apoptosis via endoplas-
mic reticulum stress-mediated JNK/CHOP/DR5 signal-
ing; (d) the combination of a-TEA + TAM had the best
impact on circumventing TAMR via decreased expres-
sion of prosurvival/antiapoptotic mediators and induc-
tion of endoplasmic reticulum stress-mediated JNK/
CHOP/DR5 proapoptotic mediators; and (e) suppression
of constitutively expressed pAkt or c-FLIP in cells by
siRNA enhanced a-TEA-induced apoptosis; as well as
endoplasmic reticulum stress-mediated JNK/CHOP/DR5
signaling, indicating an important role for crosstalk
between prosurvival Akt/antiapoptotic c-FLIP and the
pro-death endoplasmic reticulum stress pathway.
Taken together, our data for the first time demon-
strate that reducing cholesterol-rich lipid microdomains
is a promising strategy for circumventing TAMR in




b ED50 ED75 ED90 Mean + SD
d
MCF-7/TAMR 20:1 0.59 0.59 0.59 0.59 ± 0.00 Synergism
a
MCF-7/HER-2 20:1 0.68 0.80 0.94 0.81 ± 0.13 Synergism
a
aMCF-7/TAMR and MCF-7/HER-2 human breast cancer cells were treated with different concentrations of a-TEA and TAM alone and in combinations for 24 hours.
Apoptosis was determined as described in Material and Methods.
bThe ratio for concentrations used in combination treatments were determined from data in
Figure 3b and c.
cFor each combination treatment, a combination index (CI) was calculated by using methods as described previously and by using the
commercially available software (CalcuSyn; Biosoft, Manchester, United Kingdom).
dThe mean ± standard deviation (SD) is calculated from the CI values of
effective dosages (EDs) that produced 50%, 75%, and 90% apoptosis.
eCI values <1.0 indicate synergism; CI values of 1.0 indicate additive effect; and CI values
>1.0 indicate antagonism. a-TEA, RRR-a-tocopherol ether-linked acetic acid analogue; MCF-7/HER-2, clone 18 MCF-7 cells overexpressing HER-2; MCF-7/TAMR,
acquired tamoxifen-resistant MCF-7; mER, membrane estrogen receptor; TAM, tamoxifen.
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Page 6 of 12Figure 3 a-TEA alone and in combination with TAM induces apoptosis in TAMR cell lines.(a) TAM-sensitive MCF-7/parental cells and
TAMR MCF-7/TAMR and MCF-7/HER-2 cells were treated with 10, 20, and 40 μM a-TEA for 1 day. Apoptosis was determined with Annexin V/PI.
(b) MCF-7/TAMR and MCF-7/HER-2 cells were treated with 10 or 20 or 30 μM a-TEA, 0.5 or 1 or 1.5 μM TAM, and in combination for 1 day.
Apoptosis was determined with annexin V/PI/FACS assay. (c) MCF-7/TAMR and MCF-7/HER-2 cells were treated separately and in combination
with 20 μM a-TEA and 1 μM TAM for 1 day. Western blot analyses were performed to determine cleaved (c-) forms of caspases-8, 9, and PARP.
Data in (a) and (b) are depicted as mean ± SD of three individual experiments. *Significantly different in comparison with TAM and a-TEA alone;
P < 0.05. Data in (c) are representative of three individual experiments. a-TEA, RRR-a-tocopherol ether-linked acetic acid analogue; HER-2,
epidermal growth-factor receptor-2 ErbB-2; TAM, tamoxifen; TAMR, tamoxifen resistant; MCF-7/HER-2, clone 18 MCF-7 cells overexpressing HER-2;
MCF-7/TAMR, acquired tamoxifen-resistant MCF-7.
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a-TEA + TAM is a potentially beneficial regimen for
preventing and circumventing TAMR in human breast
cancer.
I ti sw e l le s t a b l i s h e dt h a tT A M Ri sc a u s e db yo v e r e x -
pression of receptor tyrosine kinases (RTKs) proteins
such as HER-1 and HER-2, which enhance RTK cross-
talk with membrane-associated estrogen receptor, result-
ing in ER-independent and -dependent cell proliferation
and survival via their downstream mediators Akt and
ERK. Akt and ERK regulate multiple prosurvival factors;
as well as activate nuclear ER-a via phosphorylation of
ER-a at Ser-118 by ERK and Ser-167 by Akt [7,30].
Furthermore, it is well established that TAM acts as an
agonist in TAMR cells stimulating prosurvival signaling
[7,30]. Thus, the combination of constitutively highly
expressed prosurvival mediators and TAM, acting as an
agonist rather than antagonist, are key molecular fea-
tures of both de novo and acquired ER+ TAMR cells.
Targeting various components in this highly amplified
prosurvival signaling context, such as HER-1, HER-2,
Akt, or mTOR, by using chemical inhibitors or
Figure 4 a-TEA alone and in combination with TAM induces
biomarkers of endoplasmic reticulum stress, and siRNA
knockdowns show necessary roles for CHOP, DR5, and JNK. (a)
Western immunoblot analyses, using aliquots of cell lysates from
cells treated with 20 μM a-TEA and 1 μM TAM in Figure 3b, were
performed to assess pJNK2/1, CHOP, and DR5 (L/S) protein levels, as
well as endoplasmic reticulum stress marker GRP78 protein
expression with GAPDH as loading control. (b) MCF-7/TAMR cells
transfected with siRNAs to CHOP, DR5, and JNK as well as control
siRNA (labeled Control) were treated with TAM (1 μM)+a-TEA (20
μM) for 1 day. Western immunoblot analyses were performed to
determine degree of apoptosis, as measured by cleaved PARP
(cPARP), pJNK2/1, CHOP, and DR5 (L/S) protein levels, with GAPDH
serving as the loading control. Data from (a) and (b) are
representative of three individual experiments. CHOP, Ccaat-
enhancer-binding protein (C/EBP) homologous protein; DR5 (L/S),
death receptor 5 long/short; GAPDH, glyceraldehyde-3-phosphate
dehydrogenase; GRP78, glucose-regulated protein-78; JNK, c-Jun N-
terminal kinase; MCF-7/TAMR, acquired tamoxifen-resistant MCF-7;
PARP, poly (ADP-ribose) polymerase; siRNA, small interfering RNA;
TAM, tamoxifen; TAMR, tamoxifen resistant; a-TEA, RRR-a-tocopherol
ether-linked acetic acid analogue.
Figure 5 Combination of a-TEA + TAM acts cooperatively to
reduce prosurvival signaling in TAMR cells. (a, b) Western
immunoblot analyses using aliquots of cell lysates from treated cells
in Figure 3b were performed to assess prosurvival signaling
mediators (a) and to assess antiapoptotic factors c-FLIP and Bcl-2
protein expression (b). (c) MCF-7/TAMR cells transfected with
siRNAs to Akt-1 or c-FLIP, as well as control siRNA (labeled Control),
were treated with a-TEA (20 μM) for 1 day. Western immunoblot
analyses were performed to determine PARP, pJNK2/1, CHOP, DR5
(L/S), GRP 78, pAKT, and c-FLIP protein levels, with GAPDH serving
as loading control. (a-c) Data are representative of three individual
experiments. a-TEA, RRR-a-tocopherol ether-linked acetic acid
analogue; Bcl-2, B-cell lymphoma 2; c-FLIP, cellular FLICE-inhibitory
protein; CHOP, Ccaat-enhancer-binding protein (C/EBP) homologous
protein; DR5 (L/S), death receptor 5 long/short; GAPDH,
glyceraldehyde-3-phosphate dehydrogenase; GRP78, glucose-
regulated protein-78; MCF-7/TAMR, acquired tamoxifen-resistant
MCF-7; pJNK, phosphorylated-c-Jun N-terminal kinase; siRNA, small
interfering RNA; TAM, tamoxifen; TAMR, tamoxifen resistant.
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TAMR [31-34]. However, targeting single components,
such as HER-1 or HER-2, eventually causes resistance
[35,36]. Therefore, alternative approaches are required
to circumvent TAMR.
Cholesterol-enriched lipid microdomains have been
shown to provide platforms for crosstalk among growth
factors, their receptors, and downstream mediators,
leading to activation of prosurvival signaling [10,11,37].
It has also been reported that cholesterol-enriched lipid
microdomains participate in crosstalk between mER and
growth-factor receptors [38]. Furthermore, cholesterol-
rich membrane rafts have been hypothesized to provide
privileged sites for nongenomic hormone signaling in
prostate cancer cells, which could stimulate cell prolif-
eration [39]. Therefore, disrupting cholesterol-rich lipid
microdomains holds promise as a strategy for circum-
venting TAMR via downregulation of prosurvival signal-
ing. However, little information exists on the role of
cholesterol-rich lipid microdomains in TAMR. In this
study, we examined whether alterations in the choles-
terol content of lipid rafts in TAMR cell membranes
affected cell-survival mediators. Here, for the first time,
we report that TAMR cells expressed high levels of cho-
lesterol-rich lipid microdomains, and that MbCD, a cho-
lesterol-depleting agent that is used in research to
disrupt lipid rafts, suppresses TAMR prosurvival signal-
ing and circumvents TAMR when combined with TAM
via restoration of TAM sensitivity and induction of
apoptosis. These results implicate the necessity of cho-
lesterol-enriched domains in survival of TAMR cells and
suggest that agents that can disrupt cholesterol-enriched
domains have potential as a promising strategy to cir-
cumvent TAMR when combined with TAM in ER+
breast cancer. Based on data presented here, a-TEA is
one such agent.
a-TEA exerts its anticancer actions via activation of
proapoptotic pathways and suppression of prosurvival
pathways. However, molecular details of how a-TEA
affects these prosurvival/antiapoptotic factors are not
fully understood. Previously, we reported that a-TEA
downregulates phosphatidylinositol-3-kinase (PI3K)/Akt/
ERK pathways via JNK-mediated downregulation of
insulin-receptor substrate (IRS-1) [20]. Data presented
here suggest that disruption of cholesterol-rich lipid
microdomains may be another mechanism of a-TEA
action. The data to support this notion come from data
presented here showing the following: (a) a-TEA dis-
rupts cholesterol-rich lipid microdomains; (b) addition
of exogenous cholesterol to enrich lipid microdomains
further, blocks the ability of a-TEA to suppress prosur-
vival mediators; and (c) a-TEA acts in a cooperative
manner with MbCD, a cholesterol disruptor, more
markedly to suppress TAMR prosurvival signaling. How
a-TEA disrupts cholesterol-rich lipid microdomains is
not known. Because a-TEA has been reported to
enhance ceramide accumulation in cellular membranes
[40] and ceramide-enriched lipid microdomains have
been reported to disrupt cholesterol lipid microdomains
[41], one possibility is that a-TEA disrupts cholesterol-
rich plasma membrane domains by increasing ceramide-
rich lipid microdomains.
Mechanistically, both MbCD and a-TEA cooperated
with TAM to suppress TAMR prosurvival signaling,
leading to TAM-induced apoptosis. Both agents reduced
cholesterol-rich lipid microdomains, which was demon-
strated to be critical to both MbCD and a-TEA circum-
vention of TAMR. However, although both MbCD and
Figure 6 Cholesterol-rich lipid microdomains are involved in a-
TEA + TAM circumvention of TAMR. (a) MCF-7/TAMR and MCF-7/
HER-2 cells were treated with a-TEA at 20 μM for 15 hours.
Identification of cholesterol-rich microdomains was determined by
staining the cells with fluorescein-tagged cholesterol marker Filipin
and images viewed by using a fluorescence microscope. (b) MCF-7/
TAMR cells were pretreated with 10 μM exogenous cholesterol for 2
hours, followed by treatment with 20 μM a-TEA or 20 μM a-TEA
plus 1 μM TAM for l day. Western blot analyses were performed to
determine treatment effects on prosurvival signaling mediators and
PARP cleavage. (a, b) Data are representative of three independent
experiments. a-TEA, RRR-a-tocopherol ether-linked acetic acid
analogue; MCF-7/HER-2, clone 18 MCF-7 cells overexpressing HER-2;
MCF-7/TAMR, acquired tamoxifen-resistant MCF-7; PARP, poly (ADP-
ribose) polymerase; TAM, tamoxifen; TAMR, tamoxifen resistant.
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TAMR cells the mechanisms are not the same. a-TEA
+ TAM induces endoplasmic reticulum stress-mediated
JNK/CHOP/DR5 proapoptotic events, whereas MbCD +
TAM did not induce endoplasmic reticulum stress (data
not shown). In summary, a-TEA + TAM induces apop-
tosis not only via suppression of prosurvival pathways,
but also via activation of endoplasmic reticulum stress-
mediated pro-apoptotic events, demonstrating that the
a-TEA + TAM combination is a unique regimen for
circumvention of TAMR.
How TAM cooperatively acts with a-TEA to induce
endoplasmic reticulum stress-mediated JNK/CHOP/DR5
is not entirely clear. One possibility is that crosstalk
Figure 7 Proposed signaling pathways modulated by a-TEA and TAM in TAMR cells. Based on published data and data presented here, a
schematic diagram of the actions of a-TEA, MbCD, and TAM on proapoptotic and prosurvival signaling mediators in TAMR cells is depicted. (a)
Proapoptotic pathway affected by a-TEA and a-TEA + TAM: a-TEA triggers DR5 extrinsic death receptor-mediated caspase-8/tBid/Bax/
mitochondria/caspase-9-dependent apoptosis and caspase-8-mediated endoplasmic reticulum stress-dependent upregulation of JNK/CHOP/DR5
positive-feedback loop. Combination of a-TEA + TAM enhances these apoptotic pathways via suppression of Akt-mediated c-FLIP. (b) Prosurvival
pathways affected by a-TEA, MbCD, and TAM. Both a-TEA and MbCD disrupt cholesterol-rich lipid microdomains, leading to suppression of
crosstalk between mER-a and RTKs, reduction of total and phosphoprotein levels of RTKs (HER-1 and HER-2), decreased levels of pAkt and
pERK1/2, as well as decreased levels of estrogen receptor-a activity via downregulation of nuclear estrogen receptor-a (nER-a) phosphorylation
mediated by Akt and ERK (Ser-118 and Ser-167). Both Akt and ERK mediated downstream prosurvival/antiapoptotic mediators, and nER-a
promoted proliferation/survival and inhibited apoptosis. In contrast, TAM stimulates survival signaling in TAMR cells. (c) Prosurvival pathways
affected by combination of a-TEA or MbCD + TAM: a-TEA or MbCD + TAM cooperatively act to suppress prosurvival signaling, indicating that
either a-TEA or MbCD restores TAM sensitivity by converting the TAM prosurvival (agonistic) actions to antisurvival (antagonistic) actions. c-FLIP,
cellular FLICE-inhibitory protein; CHOP, Ccaat-enhancer-binding protein (C/EBP) homologous protein; DR5 (L/S), death receptor 5 long/short; HER-
1, epidermal growth factor receptor ErbB-1; HER-2, epidermal growth factor receptor-2 ErbB-2; JNK, c-Jun N-terminal kinase; MCF-7/HER-2, clone
18 MCF-7 cells overexpressing HER-2; MCF-7/TAMR, acquired tamoxifen-resistant MCF-7; mER, membrane estrogen receptor; MbCD, methyl-b-
cyclodextrin; nER, nuclear estrogen receptor; pAkt, phosphorylated-Akt; pERK1/2, phosphorylated-extracellular signal-regulated kinases 1 and2 ;
RTKs, receptor tyrosine kinases; TAM, tamoxifen; TAMR, tamoxifen resistant; tBid, truncated Bid; a-TEA, RRR-a-tocopherol ether-linked acetic acid
analogue.
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signaling and induction of endoplasmic reticulum stress.
Published data show that downregulation of c-FLIP can
enhance the a-TEA-induced endoplasmic reticulum
stress proapoptotic pathway via activation of caspase-8,
because caspase-8 is involved in a-TEA-induced endo-
plasmic reticulum stress [18]. Data presented here show
that siRNA to Akt-1 blocked c-FLIP protein expression,
suggesting that Akt is an upstream mediator of c-FLIP.
Furthermore, siRNA inhibition of either Akt-1 or c-FLIP
enhanced a-TEA-induced endoplasmic reticulum stress
and endoplasmic reticulum stress-mediated upregulation
of JNK/CHOP/DR5, indicating that suppression of pro-
survival mediators by TAM + a-TEA may enhance a-
TEA-induced endoplasmic reticulum stress-mediated
JNK/CHOP/DR5, at least in part, via downregulation of
activated Akt, which subsequently downregulates c-FLIP.
Based on published data and data present here, a
schematic diagram of the known actions of a-TEA,
MbCD, and TAM on proapoptotic and prosurvival sig-
naling in TAMR cells is depicted in Figure 7.
Conclusions
In summary, a-TEA functions as a disruptor of choles-
terol-rich lipid microdomains and an endoplasmic reti-
culum stress inducer in circumvention of TAMR.
Although a-TEA can effectively induce TAMR cells to
undergo apoptosis as a single agent, it acts cooperatively
with TAM at lower dosages to activate endoplasmic
reticulum stress-mediated proapoptotic events and sup-
presses the highly amplified prosurvival signaling inher-
ent in TAMR cells. As a potent anticancer agent, a-
TEA possesses several compelling features: (a) low toxi-
city to normal cells and tissues [12]; (b) dual anticancer
actions (that is, suppresses prosurvival mediators and
activates proapoptotic mediators); and (c) is effective
against a wide range of cancer cell types with disparate
molecular signatures [42]. Unlike single agents that tar-
g e tH E R - 1 ,H E R - 2 ,A k t ,o rm T O R ,a-TEA can inhibit
multiple prosurvival mediators via disruption of choles-
terol-rich lipid microdomains and induce apoptosis.
These unique features of a-TEA suggest great potential
for use as a stand-alone adjuvant therapy or in combina-
tion with the adjuvant TAM for prevention and circum-
vention of TAMR in ER+ human breast cancers.
Additionally, these data provide new knowledge about
mechanisms of endocrine therapy resistance that may be
useful in designing other agents for circumvention of
TAMR.
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